ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote,
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
|
29,947,985 |
99.73 % |
81,989 |
0.27 % |
Richard MGlickman |
29,948,035 |
99.73 % |
81,939 |
0.27 % |
|
29,945,788 |
99.72 % |
84,186 |
0.28 % |
|
29,937,249 |
99.69 % |
92,725 |
0.31 % |
|
29,947,985 |
99.73 % |
81,989 |
0.27 % |
MarellaThorell |
23,840,414 |
79.39 % |
6,189,560 |
20.61 % |
|
30,014,431 |
99.95 % |
15,543 |
0.05 % |
|
30,013,358 |
99.94 % |
16,616 |
0.06 % |
|
30,014,381 |
99.95 % |
15,593 |
0.05 % |
|
30,015,635 |
99.95 % |
14,339 |
0.05 % |
At the Meeting, the Shareholders also approved: (i) the re-appointment of
Contact Information:
Chief Financial Officer,
T: 778-331-0962
E: dwood@essapharma.com
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302083628.html
SOURCE